Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.42 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23775453 | 0.86 | TRPV1 (0.51) | TRPV1ABCB1KDM4AALDH1A1 | |
| SCHEMBL30305208 | 0.86 | TRPV1 (0.51) | TRPV1ABCB1KDM4AALDH1A1 | |
| SCHEMBL192397 | 0.86 | APLNR (0.56) | ABCB1ALDH1A1GAA | |
| SCHEMBL2948649 | 0.85 | GAA (0.50) | TRPV1ABCB1KDM4AALDH1A1GAA | |
| SCHEMBL17674375 | 0.85 | ALDH1A1 (0.45) | TRPV1ABCB1KDM4AALDH1A1GAA | |
| SCHEMBL2950863 | 0.84 | CA12 (0.49) | TRPV1ABCB1KDM4A | |
| SCHEMBL12231290 | 0.84 | POLB (0.44) | TRPV1ABCB1KDM4AALDH1A1ITGA4 | |
| SCHEMBL12231412 | 0.84 | MAPT (0.47) | TRPV1ABCB1KDM4AALDH1A1DRD2 | |
| SCHEMBL31044381 | 0.83 | TRPV1 (0.42) | TRPV1ABCB1KDM4AGAADRD2 | |
| SCHEMBL32665544 | 0.82 | CA12 (0.49) | NQO2KDM4AEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011078370-A1 | NOVEL PARABANIC ACID DERIVATIVE AND DRUG HAVING THE SAME AS ACTIVE INGREDIENT | 杏林製薬株式会社 (JP) | 2011-06-30 | — | — | WO | disclosed |
| US-7750040-B2 | G protein-coupled receptor S1P1/EDG1 agonists; low dosage, long lasting immunosuppressive effect; such as 1,1,2-trimethyl-1,1a,5,5a-tetrahydro-3-thia-cyclopropa[a]pentalene-4-carboxylic acid 2,4-dimethoxy-benzylamide | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-06 | — | — | US | disclosed |
| EP-1805163-B1 | 1,1A,5,5A-TETRAHYDRO-3-THIA-CYCLOPROPA[A]PENTALENES: TRICYCLIC THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-10-01 | — | — | EP | disclosed |
| US-20080064740-A1 | Novel Thiophene Derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2008-03-13 | — | — | US | disclosed |
| EP-1805163-A2 | 1,1A,5,5A-TETRAHYDRO-3-THIA-CYCLOPROPA¬A|PENTALENES: TRICYCLIC THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006010379-A1 | NOVEL THIOPHENE DERIVATIVES AS IMMUNOSUPPRESSIVE AGENTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-02-02 | — | — | WO | disclosed |
| WO-2006010544-A2 | 1, 1A, 5, 5A-TETRAHYDRO-3-THIA-CYCLOPROPA’A! PENTALENES: TRICYCLIC THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064740-A1 | Novel Thiophene Derivatives | TPMT, TSLP, NFATC1 | NQO2 2973/4885MAOB 4403/4885TRPV1 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.